Mpox Paediatric and Adolescent Clinical Study
1 other identifier
observational
1,108
6 countries
6
Brief Summary
The goal of this multicentre, observational study on mpox in infants, children and adolescents is to increase knowledge about mpox infection and its associated disease in infants, children and adolescents. This will be done through the development of a harmonized system that will allow standard collection of information on demographics, clinical symptoms, clinical course, treatments and outcomes. The study will be carried out in three potential phases: Phase 1 entails the rapid development of an online paediatric registry collecting anonymised data from routine care on infants, children and adolescents with laboratory-confirmed mpox virus infection. If warranted, the study will proceed to Phase 2, an enhanced observational study of children and adolescents with confirmed mpox virus infection, if more detailed prospective data collection would aid the public health response. There is also the potential to initiate Phase 3, comprising of nested sub-studies to investigate specific research questions in this population.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2023
Typical duration for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 17, 2023
CompletedFirst Submitted
Initial submission to the registry
May 26, 2023
CompletedFirst Posted
Study publicly available on registry
July 17, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
October 31, 2025
CompletedResults Posted
Study results publicly available
August 31, 2026
CompletedAugust 31, 2026
July 1, 2026
2.6 years
May 26, 2023
December 23, 2025
July 6, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Proportion of Participants With Severe Mpox.
Severe mpox infection as measured by, for example, mortality, ICU admission, receipt of interventions
Throughout the study period. Participants are enrolled over a period of 2 years 7 months, participants' outcomes are recorded at 28 days.
Secondary Outcomes (1)
Number of Infants Born to Women Infected With Mpox in Pregnancy, Who Are Vertically Infected With Mpox.
Throughout the study period. Participants are enrolled over a period of 2 years 7 months, participants' outcomes are recorded at 28 days.
Eligibility Criteria
Infants, children and adolescents with laboratory-confirmed mpox infection, including adolescent girls who acquired mpox in pregnancy, and infants who acquired mpox through vertical transmission. Phase 1 participants' consent may not be necessary as data collected is anonymous, phase 2 observational study participation would require participants'/ parent or legal representative consent as data collected is pseudonymised.
You may qualify if:
- all infants, children and adolescents aged \<18 years at the time of mpox diagnosis, with laboratory-confirmed mpox infection, as per national guidelines;
- mothers of eligible infants who are diagnosed with mpox at 28days or less are included in the study to collect maternal data on pregnancy and delivery
You may not qualify if:
- adolescents aged over 18 years old at mpox diagnosis.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- PENTA Foundationlead
- University College, Londoncollaborator
- European University Cypruscollaborator
- Servicio Madrileño de Salud, Madrid, Spaincollaborator
- European Commissioncollaborator
Study Sites (6)
Seattle Children's Hospital
Seattle, Washington, 98105, United States
University of Kinshasa
Kinshasa, Democratic Republic of the Congo
Noguchi Memorial Institute for Medical Research
Accra, Ghana
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Mexico City, Mexico
Institute of Human Virology Nigeria
Abuja, Nigeria
Hospital La Paz
Madrid, Spain
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Results Point of Contact
- Title
- Charlotte Jackson
- Organization
- University College London
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- NETWORK
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 26, 2023
First Posted
July 17, 2023
Study Start
March 17, 2023
Primary Completion
October 31, 2025
Study Completion
October 31, 2025
Last Updated
August 31, 2026
Results First Posted
August 31, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share